<p><h1>Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Market Research Report Provides Critical Insights that can help Shape Business Development and Investment Strategies</h1></p><p><strong>Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Market Analysis and Latest Trends</strong></p>
<p><p>The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market is poised for significant growth, driven by increasing awareness of the disease and advancements in treatment options. ATTR-CM, a progressive condition caused by the accumulation of misfolded transthyretin protein in the heart, presents unique challenges for diagnosis and management. With the introduction of novel therapeutics and a growing pipeline of effective treatments, the market is expected to flourish.</p><p>The market is projected to grow at a CAGR of 8.8% during the forecast period of 2022-2028, reflecting the rising demand for innovative therapies aimed at improving patient outcomes. Key trends include the development of disease-modifying therapies, targeted monoclonal antibodies, and gene silencing approaches that are expected to enhance treatment efficacy. Additionally, increased investment in research and development, along with collaboration between pharmaceutical companies and academic institutions, is likely to drive growth.</p><p>The rising incidence of ATTR-CM, coupled with a growing geriatric population, is further fueling market expansion. As healthcare providers become more equipped to diagnose and manage this condition, the ATTR-CM treatment landscape will continue to evolve, offering promising opportunities for stakeholders in the market.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliablebusinessinsights.com/enquiry/request-sample/1068435">https://www.reliablebusinessinsights.com/enquiry/request-sample/1068435</a></p>
<p>&nbsp;</p>
<p><strong>Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Major Market Players</strong></p>
<p><p>The Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is experiencing significant growth, driven by increasing awareness, advancements in therapeutic options, and a growing patient population. Major players in this space include Pfizer Inc., GlaxoSmithKline Plc, Eidos Therapeutics, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Prothena Corporation Plc, Intellia Therapeutics, and Corino Therapeutics.</p><p>Pfizer Inc. leads the market with its drug, tafamidis, which has gained approval for ATTR-CM and is projected to drive substantial revenue due to strong uptake and increased diagnoses. Pfizer reported revenues of $89 billion in 2021, with a notable contribution from its rare disease portfolio. </p><p>Alnylam Pharmaceuticals is another key player, specializing in RNA interference therapies. Their drug, patisiran, is FDA-approved and has shown promise in improving cardiac outcomes in ATTR-CM patients. In 2022, Alnylam reported revenues of $344 million, bolstered by the success of patisiran.</p><p>Eidos Therapeutics, acquired by BridgeBio Pharma, is also gaining traction with its novel treatment for ATTR-CM, acoramidis, which targets early disease stages. Both the market size and future growth prospects appear robust, with an expected CAGR in the double-digit percentages through 2028.</p><p>Ionis Pharmaceuticals focuses on antisense oligonucleotide therapies, developing options aimed at reducing transthyretin production. Prothena Corporation is advancing therapies in clinical trials targeting various aspects of ATTR-CM.</p><p>The competitive landscape is poised to evolve, emphasizing collaboration among biotechnology firms and an increasing pipeline of innovative therapies. As the global market moves towards a valuation exceeding $2 billion by 2028, players are focusing on clinical advancements and strategic partnerships to capture market share and fulfill unmet patient needs in ATTR-CM treatment.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Manufacturers?</strong></p>
<p><p>The Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is poised for significant growth from 2022 to 2028, driven by increasing awareness and diagnosis of the condition. Key players are investing in innovative therapies, including gene silencing and stabilizers like tafamidis, which have shown promise in clinical trials. The market is expected to expand due to rising incidences of ATTR-CM, an aging population, and improvements in healthcare infrastructure. Additionally, ongoing research into combination therapies could enhance treatment efficacy. By 2028, the market is projected to witness a CAGR of over 20%, reflecting robust demand for effective management options.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/1068435">https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/1068435</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Transthyretin Stabilizers</li><li>Nonsteroidal Anti-inflammatory Drugs (NSAID)</li><li>RNAi Therapy</li><li>Others</li></ul></p>
<p><p>The Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is projected to grow significantly between 2022 and 2028, driven by increasing diagnoses and advanced therapeutic options. Key market types include transthyretin stabilizers that prevent protein misfolding, nonsteroidal anti-inflammatory drugs (NSAIDs) that alleviate symptoms, and RNA interference (RNAi) therapies that target the underlying genetic causes. Other treatments may encompass supportive therapies and novel drug candidates. The global outlook indicates a rising demand for effective ATTR-CM therapies, enhancing patient outcomes and quality of life.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliablebusinessinsights.com/purchase/1068435">https://www.reliablebusinessinsights.com/purchase/1068435</a></p>
<p>&nbsp;</p>
<p><strong>The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hereditary Transthyretin Amyloidosis (hATTR)</li><li>Wild Type Transthyretin Amyloidosis (wtATTR)</li></ul></p>
<p><p>The Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is poised for significant growth, driven by increasing awareness and diagnosis of both hereditary transthyretin amyloidosis (hATTR) and wild-type transthyretin amyloidosis (wtATTR). Innovative therapies, including gene silencing and stabilization agents, are advancing patient care. The market outlook from 2022 to 2028 is positive, with expanding therapeutic options and clinical trials expected to enhance treatment effectiveness and accessibility, catering to diverse patient needs across global regions.</p></p>
<p><a href="https://www.reliablebusinessinsights.com/transthyretin-amyloid-cardiomyopathy-treatment-market-in-global-r1068435">&nbsp;https://www.reliablebusinessinsights.com/transthyretin-amyloid-cardiomyopathy-treatment-market-in-global-r1068435</a></p>
<p><strong>In terms of Region, the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2022-2028 Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global ATTR-CM treatment market is projected to experience significant growth from 2022 to 2028, driven by increasing awareness and advancements in therapeutic options. North America is anticipated to dominate the market with a share of approximately 50%, leveraging a well-established healthcare infrastructure. Europe follows with around 30%, benefiting from rising diagnosis rates, while APAC, including China, is expected to capture 15% as a growing focus on rare diseases enhances treatment accessibility. The remaining 5% is attributable to other regions.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliablebusinessinsights.com/purchase/1068435">https://www.reliablebusinessinsights.com/purchase/1068435</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliablebusinessinsights.com/enquiry/request-sample/1068435">https://www.reliablebusinessinsights.com/enquiry/request-sample/1068435</a></p>
<p><strong></strong></p>
<p><p><a href="https://www.linkedin.com/pulse/hafnium-crystal-bar-market-share-size-trends-industry-analysis-imcpe?trackingId=5sRV%2BjKDQa%2Btm7HrynpOZQ%3D%3D">Hafnium Crystal Bar Market</a></p><p><a href="https://www.linkedin.com/pulse/pasted-valve-bags-market-size-growth-trends-statistics-ggnae?trackingId=jt6esZXBR3KU6owm0YB3DQ%3D%3D">Pasted Valve Bags Market</a></p><p><a href="https://www.linkedin.com/pulse/global-noble-ingredients-market-status-2024-2031-forecast-ppvnc?trackingId=gE6er6iHQfycEnEqj8GENg%3D%3D">Noble Ingredients Market</a></p><p><a href="https://www.linkedin.com/pulse/iv-tube-market-report-product-type-pediatricadultgeriatric-nzmte?trackingId=7HG3efwJQEubKEAGcz6v0A%3D%3D">IV Tube Market</a></p><p><a href="https://www.linkedin.com/pulse/global-blueberry-juice-market-share-growth-opportunities-size-zhohc?trackingId=%2FYAUwsjDRVOo9qmC67dHBg%3D%3D">Blueberry Juice Market</a></p></p>